57 related articles for article (PubMed ID: 23773821)
1. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect.
Pore SK; Choudhary A; Rathore B; Ganguly A; Sujitha P; Kumar CG; Agawane SB; Kumar JM; Scaria V; Pillai B; Banerjee R
Biomaterials; 2013 Sep; 34(28):6804-17. PubMed ID: 23773821
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer.
Jinka S; Rachamalla HK; Bhattacharyya T; Sridharan K; Sekhar Jaggarapu MMC; Yakati V; Banerjee R
Biomed Mater; 2021 Feb; 16(2):024105. PubMed ID: 33434900
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.
Mondal SK; Jinka S; Pal K; Nelli S; Dutta SK; Wang E; Ahmad A; AlKharfy KM; Mukhopadhyay D; Banerjee R
Mol Pharm; 2016 Jul; 13(7):2507-23. PubMed ID: 27184196
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
Kovacs JJ; Murphy PJ; Gaillard S; Zhao X; Wu JT; Nicchitta CV; Yoshida M; Toft DO; Pratt WB; Yao TP
Mol Cell; 2005 May; 18(5):601-7. PubMed ID: 15916966
[TBL] [Abstract][Full Text] [Related]
7. Differential alteration of heat shock protein 90 in mice modifies glucocorticoid receptor function and susceptibility to trauma.
Shen HY; Zhao Y; Chen XY; Xiong RP; Lu JL; Chen JF; Chen LY; Zhou YG
J Neurotrauma; 2010 Feb; 27(2):373-81. PubMed ID: 19845467
[TBL] [Abstract][Full Text] [Related]
8. Delimitation of two regions in the 90-kDa heat shock protein (Hsp90) able to interact with the glucocorticosteroid receptor (GR).
Jibard N; Meng X; Leclerc P; Rajkowski K; Fortin D; Schweizer-Groyer G; Catelli MG; Baulieu EE; Cadepond F
Exp Cell Res; 1999 Mar; 247(2):461-74. PubMed ID: 10066374
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
10. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor.
Mukherjee A; Narayan KP; Pal K; Kumar JM; Rangaraj N; Kalivendi SV; Banerjee R
Mol Ther; 2009 Apr; 17(4):623-31. PubMed ID: 19223869
[TBL] [Abstract][Full Text] [Related]
11. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GR-mediated transcription by p23 requires interaction with Hsp90.
Wochnik GM; Young JC; Schmidt U; Holsboer F; Hartl FU; Rein T
FEBS Lett; 2004 Feb; 560(1-3):35-8. PubMed ID: 14987994
[TBL] [Abstract][Full Text] [Related]
13. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
14. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
15. Stress type dependence of expression and cytoplasmic-nuclear partitioning of glucocorticoid receptor, hsp90 and hsp70 in Wistar rat brain.
Djordjevic A; Adzic M; Djordjevic J; Radojcic MB
Neuropsychobiology; 2009; 59(4):213-21. PubMed ID: 19521113
[TBL] [Abstract][Full Text] [Related]
16. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.
Nakashima T; Ishii T; Tagaya H; Seike T; Nakagawa H; Kanda Y; Akinaga S; Soga S; Shiotsu Y
Clin Cancer Res; 2010 May; 16(10):2792-802. PubMed ID: 20406843
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
Zhang Q; Zhai S; Li L; Li X; Zhou H; Liu A; Su G; Mu Q; Du Y; Yan B
Biochem Pharmacol; 2013 Aug; 86(3):351-60. PubMed ID: 23743233
[TBL] [Abstract][Full Text] [Related]
18. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
20. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
